Skip to main content
OpenTrials
Completed

NCT Number: NCT04138017

ViviGen Cellular Bone Matrix for Hindfoot or Ankle Arthrodesis

To evaluate the fusion status of the hindfoot bones after receiving the ViviGen graft, an FDA approved cellular bone matrix. This is used in a population indicated for hindfoot arthrodesis as an alternative to an autograft.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

University of Virginia

Charlottesville, Virginia, 22908, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patient with prescribed standard of care unilateral hindfoot ankle arthrodesis procedure
  • Age 18-80
  • Willing to complete all follow up evaluations

Exclusion criteria

  • Prior infection at site of planned arthrodesis
  • Prior arthrodesis procedure
  • Inability to maintain non-weight bearing status
  • Bone defect requiring more than 10 cc of bone graft material
  • Known Vitamin D deficiency with a Vitamin D level of <30ng/ml 1 week prior to surgery
  • Inadequate bone stock to allow for rigid internal fixation
  • Hemoglobin A1c greater than 8.0%
  • Tobacco or Nicotine use 6 weeks prior to surgery
  • BMI greater than 40

Treatment and study plan

ViviGen

Device

A cellular bone matrix which includes viable osteoblasts within a corticocancellous and demineralized bone carrier, represents a unique alternative to autograft or existing products which utilize mesenchymal stem cells.

Primary outcomes

  1. Union Rates

    Time frame: 12 months

    Radiographic evidence of successful arthrodesis confirmed on Computed Tomography (CT) scan defined by >50%. Results are for total number of joints fused which exceeds the number of participants due to some subjects having multiple joints fused.

Secondary outcomes

  1. Failure of Hardware or Obvious Non-union

    Time frame: 12 months

    Failure measured through clinical and radiographic evidence

  2. Foot and Ankle Ability Measure (FAAM) - Activities of Daily Living (ADL) Subscale

    Time frame: baseline, 3 month, 6 month, 1 year

    For this study, the researchers only utilized the ADL subscale. This patient-reported outcome measure is a 21-item questionnaire assessing fundamental mobility and daily activities. Responses use a 5-point Likert scale ranging from 4 (no difficulty) to 0 (unable to do), with N/A responses excluded. The responses are summed, and the total possible score is calculated by multiplying the number of answered items by 4 (maximum score: 84). The total score is divided by the highest potential score, then multiplied by 100 to yield a percentage. Higher percentages indicate greater physical function, with 100% representing no functional limitations, on the ADL subscale.

  3. Vitamin D Levels

    Time frame: baseline, 6 months

    25-Hydroxyvitamin D is the primary circulating form of vitamin D and is the most commonly used measure to assess vitamin D status in the blood. The reference range for 25-hydroxy vitamin D test is 20-80 ng/mL. A low test level would indicate lower concentrations of Vitamin D.

  4. American Orthopaedic Foot and Ankle Society(AOFAS) Hindfoot Score

    Time frame: baseline, 3 month, 6 month, 1 year

    Patient reported outcome for a standardized evaluation of clinical status of ankle- hindfoot. Patient reports their pain and the physician records physical assessment of alignment. Finally function is reported and the AOFAS score ranged from 0-100 with 100 being healthy ankles.

Sponsors and collaborators

Lead sponsor

University of Virginia

Other

Collaborators

  • DePuy Synthes

Registry information

Official study title

Clinical and Radiographic Outcomes Using ViviGen® Cellular Bone Matrix for Complex Hindfoot Arthrodesis

Acronym: ViviGen

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
Oct 24, 2019
Registry last updated
Jun 19, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.